 The primary objective of the study is to evaluate the non-inferiority in efficacy of a standardised dosage regimen of FERINJECT compared to individually calculated dosage regimens of VENOFER in the correction of IDA in patients with IBD in remission. The secondary objective is to evaluate the safety and tolerability of a standardised correction dose regimen of FERINJECT. 